Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors though it is unlikely that these properties contribute to its therapeutic effects.Renzapride was being developed by Alizyme plc of the United Kingdom.
This page contains content from the copyrighted Wikipedia article "Renzapride"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
